Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury

Genovese T., Cuzzocrea S., Di Paola R., Mazzon E., Mastruzzo C., Catalano P., Sortino M., Crimi N., Caputi A. P., Thiemermann C., Vancheri C.

Source: Eur Respir J 2005; 25: 225-234
Journal Issue: February

Congress or journal article abstractPDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Genovese T., Cuzzocrea S., Di Paola R., Mazzon E., Mastruzzo C., Catalano P., Sortino M., Crimi N., Caputi A. P., Thiemermann C., Vancheri C.. Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25: 225-234

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Role of exogenous ligands for the peroxisome proliferator-activated receptor-β/δ in the development of bleomycin-induced lung injury
Source: Annual Congress 2010 - Cell biology and immunology of lung disease
Year: 2010

Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury
Source: Eur Respir J 2008; 32: 1344-1353
Year: 2008



Effects of peroxisome proliferators-activated receptor-α, γ agonists on acute lung injury rats induced by lipopolysaccharide
Source: Eur Respir J 2006; 28: Suppl. 50, 397s
Year: 2006

Role of NF-?B and PPAR-? in lung inflammation induced by monocyte-derived microparticles
Source: Eur Respir J 2011; 37: 1494-1502
Year: 2011



Preserved compliance and reduced inflammation after activation of peroxisome proliferator-activated receptor (PPAR)a in a murine model of acute lung injury
Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS)
Year: 2006


Peroxisome proliferator-activated receptors: a therapeutic target in COPD?
Source: Eur Respir J 2008; 31: 502-508
Year: 2008



Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD
Source: Eur Respir J 2007; 30: 245-252
Year: 2007



Impacts of peroxisome proliferator-activated receptor gamma activation on cigarette smoke-induced exacerbated response to bacteria
Source: Eur Respir J 2015; 45: 191-200
Year: 2015



The effect of peroxisome proliferator-activated receptor-? ligands on in vitro and in vivo models of COPD
Source: Eur Respir J 2014; 43: 409-420
Year: 2013



PPAR-γ agonists as therapy for diseases involving airway neutrophilia
Source: Eur Respir J 2004; 24: 18-23
Year: 2004



Peroxisome proliferator-activated receptor γ inhibits acrolein-induced airway mucus hypersecretion in rats
Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD
Year: 2008


Activation of airway epithelial cell inhibited by peroxisome proliferator-activated receptor γ
Source: Eur Respir J 2006; 28: Suppl. 50, 229s
Year: 2006

Relationship between peroxisome proliferator-activated receptor α and neutrophils in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 452s
Year: 2004

The effects of exercise training on peroxisome proliferator-activated receptor (PPAR) expression in skeletal muscle in COPD
Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation
Year: 2009

Peroxisome proliferator-activated receptor gamma (PPARγ) protects against pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2007; 30: Suppl. 51, 6s
Year: 2007

Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 856s
Year: 2006

Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease
Source: Eur Respir Rev 2006; 15: 211-212
Year: 2006



The interaction of glucocorticoid and peroxisome proliferator-activated receptor γ agonist in asthmatic mice
Source: Eur Respir J 2006; 28: Suppl. 50, 226s
Year: 2006

Naftopidil, a selective a1 adrenoceptor antagonist, inhibits the growth of lung fibroblasts and attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017

Peroxisome proliferator activated receptor gamma (PPARγ) agonist rosiglitizone inhibits upregulation of mucin gene expression in two airway epithelial cell lines
Source: Eur Respir J 2005; 26: Suppl. 49, 97s
Year: 2005